Incyte Corporation — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2018. Unaudited consolidated results. Incyte is a biopharmaceutical company whose marketed products include U.S. JAKAFI and European ICLUSIG; it also earns royalties and milestone revenue from collaborators.
Financial performance
Amounts are in millions of U.S. dollars, except per-share data. Comparisons are with the corresponding 2017 period.
| Metric | Q3 2018 | Q3 2017 | Nine months 2018 | Nine months 2017 |
|---|---|---|---|---|
| Total revenue | $449.7 | $381.5 | $1,353.5 | $1,092.1 |
| Operating income (loss) | $31.1 | $15.0 | $47.2 | ($111.0) |
| Net income (loss) | $29.2 | $36.1 | $40.4 | ($163.5) |
| Diluted EPS | $0.14 | $0.17 | $0.19 | ($0.81) |
| Operating cash flow | Not provided for quarter | Not provided for quarter | $252.4 | ($3.7) |
- Revenue rose approximately 18% in Q3 and 24% for the nine-month period. Q3 growth included higher JAKAFI sales and royalties, but lower investment-related results and an unfavorable contingent-consideration remeasurement contributed to lower net income than a year earlier.
- JAKAFI net revenue was $347.6 million in Q3 and $1,006.9 million for nine months; ICLUSIG revenue was $20.1 million and $60.8 million, respectively. Product royalties were $61.9 million and $165.6 million; milestone revenue was $20.0 million and $120.0 million.
- Nine-month operating expenses were $67.8 million cost of product revenue, $893.7 million R&D, and $326.0 million SG&A. R&D increased 1.6% year over year and SG&A increased 21.4%. The filing attributes R&D trends partly to prior-year collaboration upfront and milestone expenses and increased current-period pipeline spending.
- Cash, cash equivalents and current marketable securities totaled approximately $1.375 billion at September 30; management described available cash, cash equivalents and marketable securities as $1.4 billion. Current assets were $1.700 billion and current liabilities $422.5 million.
- Nine-month investing cash outflow was $50.3 million, including $48.2 million of capital expenditures; financing cash inflow was $10.6 million. Cash, cash equivalents, restricted cash and investments increased $212.8 million over the period.
- Convertible-note carrying value was $24.9 million ($7.6 million due in 2018 and $17.2 million due in 2020); contractual principal was $26.8 million. Acquisition-related contingent consideration had a reported fair value of $286.0 million, primarily tied to future ICLUSIG royalties and milestones to Takeda.
Material changes and notable items
- JAKAFI revenue increased year over year, reflecting both volume and price increases. The company cautioned that customer purchasing patterns and price-related government rebates and chargebacks can affect quarterly net sales.
- OLUMIANT’s U.S. 2 mg dose was approved in June 2018 for specified rheumatoid arthritis patients. In the first nine months, this approval generated a $100 million Lilly milestone; a further $20 million milestone followed the first patient treated in the baricitinib systemic lupus erythematosus Phase III program.
- The nine-month 2017 comparison included $54.9 million of expense related to senior-note conversions and a $12.0 million acquired in-process R&D impairment; neither was recorded in the 2018 period. The 2017 period also included a $649.4 million public-offering cash inflow.
- At September 30, long-term investments were $121.4 million. Mark-to-market losses included $19.9 million on Agenus and $5.3 million on Calithera for the nine months; these investment movements can make reported earnings volatile.
Outlook, risks and contingencies
- No specific revenue or earnings guidance is stated in the supplied filing text. Management said cash, cash equivalents, marketable securities and operating cash flow should meet capital needs for the foreseeable future, while noting that future spending depends on pipeline development, commercialization, facilities and strategic arrangements.
- Pipeline highlights included an FDA Priority Review for the ruxolitinib acute GVHD supplemental application, ongoing Phase III GVHD studies, and positive interim pemigatinib data in cholangiocarcinoma announced in October 2018. Clinical outcomes, regulatory review and milestone receipts remain uncertain.
- Incyte stopped the epacadostat ECHO-301 study with Merck in April 2018 and significantly downsized that program. The filing also identifies regulatory, clinical-trial, manufacturing, reimbursement, competition and product-safety risks.
- JAKAFI sales are material to revenue and exposed to reimbursement, pricing, distribution and generic-entry risks. The filing describes an ANDA challenge to certain ruxolitinib patents; it also states the FDA had taken no action on that ANDA as of the report.
- Incyte held approximately 16% of Agenus. Agenus had disclosed substantial doubt about its ability to continue as a going concern; Incyte said it did not plan to participate in future equity fundraising and anticipated possible dilution and a significant permanent decline in investment value.
- Incyte began construction of a planned Swiss large-molecule production facility, with completion anticipated in the second half of 2020. It also signed a 15-year lease for a renovated European headquarters in Morges. These projects add capital and future occupancy commitments.
- Management reported disclosure controls were effective at the reasonable-assurance level and no material change in internal control over financial reporting during the quarter.
Key facts for investors to verify
- Whether JAKAFI growth, pricing and reimbursement trends continue, and how government rebates, chargebacks and customer concentration affect net sales.
- How much future revenue and earnings depend on partner milestones and royalties, particularly Lilly-related milestones and sales.
- Clinical, regulatory and commercial progress for ruxolitinib in GVHD, pemigatinib, itacitinib and other priority programs, including the specified OLUMIANT label and warning.
- The sensitivity of earnings and balance-sheet values to collaborator-investment prices and the Level 3 contingent-consideration estimates.
- Cash deployment, facility spending and lease commitments, alongside R&D and SG&A growth and operating cash generation.
- The status and potential consequences of the JAKAFI patent challenge, and Agenus’s financing outlook and implications for Incyte’s investment.
- The MD&A contains an apparent comparative-period wording inconsistency: it describes Q3 2017 net income while referring to net loss per share; the financial statements report Q3 2017 net income of $36.1 million and EPS of $0.17.